Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vertex Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 3.97.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vertex Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Vertex Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
MEX:VRTX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.38 Med: 5.98 Max: 16.02
Current: 3.97
During the past 13 years, Vertex Pharmaceuticals's highest Cash to Debt Ratio was 16.02. The lowest was 1.38. And the median was 5.98.
MEX:VRTX's Cash-to-Debt is ranked worse than 57.7% of 1397
companies
in the Biotechnology industry
Industry Median: 6.72
vs MEX:VRTX: 3.97
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Vertex Pharmaceuticals Cash-to-Debt Related Terms
Vertex Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:VRTX vs REGN, MRNA, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (MEX:VRTX) has a Cash-to-Debt of 3.97 as of Jun. 2026. This is 34% below median its historical median of 5.98. Over the past decade, Vertex Pharmaceuticals' Cash-to-Debt has ranged from 1.38 to 16.02. According to the industry distribution chart, Vertex Pharmaceuticals ranks #806 out of 1397 companies in the Biotechnology industry, placing it in the top 57.7%.
Is Vertex Pharmaceuticals' Cash-to-Debt too high?
Vertex Pharmaceuticals' current Cash-to-Debt of 3.97 is 34% below median its 10-year median of 5.98. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 16.02. The Biotechnology industry median Cash-to-Debt is 6.72. Vertex Pharmaceuticals' value of 3.97 is 40.9% below this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #806 out of 1397 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Cash-to-Debt compare to REGN and MRNA?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #806 out of 1397 companies for Cash-to-Debt. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median Cash-to-Debt is 6.72. Vertex Pharmaceuticals' value of 3.97 is 40.9% below this benchmark. Historically, Vertex Pharmaceuticals' own Cash-to-Debt has ranged from 1.38 to 16.02 over the past decade. While the company's 10-year median is 5.98 vs. the industry median of 6.72, Vertex Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current Cash-to-Debt of 3.97 is 40.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current Cash-to-Debt is 3.97, which is 34% below median its own 10-year median of 5.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,871.51, compared to a current price of MXN8,963.36 — trading 1% above its estimated fair value. The current Cash-to-Debt is 3.97, which is 34% below median its 10-year median of 5.98 and 40.9% below the Biotechnology industry median of 6.72. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Cash-to-Debt is 3.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN8,963.36 is trading 1% above its estimated GF Value™ of MXN8,871.51.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
Cash-to-Debt: 3.97 (34% below median its 10-year median of 5.98)
GF Value™: MXN8,871.51 vs. price of MXN8,963.36 (1% above fair value)
Industry Position: 40.9% below the Biotechnology median (#806 of 1397)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score
Get the complete analysis for MEX:VRTX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
